Medigene Presenting Innovative IFN-Gamma-Biosensor Technology at SITC 2024

DJ PTA News: Medigene AG: Medigene presents data on innovative IFN-Gamma-Biosensor Technology at SITC 2024

Unternehmensmitteilung voor de Kapitalmarkt

Planegg/Martinsried (pta/12.11.2024/13:00) – Die Medigene AG ( http://www.medigene.de/ ) (Medigene oder das “Unternehmen”, FWB: MDG1, Prime Standard) and onkological Plattformunternehmen, das see the Erforschung and Entwicklung of T-Zell-Rezeptor (TCR) immunotherapies for the treatment of specialist Krebs, presented data on the new Erweiterung in the End-to-End (E2E) platform, the interferon-Gamma (IFN-Gamma) -Biosensor-Technology, which represents a real time- monitoring and quantification of the IFN-Gamma-Freisetzung with Zytokin studies published at the conference of the Society of Immunotherapy of Cancer (SITC) 2024, from November 6 to 10, 2024 in Houston, Texas, USA, stattfand.

The poster “The IFN-Gamma Biosensor – A universal tool for IFN-Gamma detection in cellular co-culture assays” is available on the Medigene website: https://medigene.de/wissenschaft/abstracts/

“The Freisetzung of IFN-Gamma is one of the higher methods for the functional messaging of T-Zellen or NK-Zellen. The time methods for the IFN-Gamma-Sekretion are more nocturnal, last a long period of time and the notekeit teurer, temperaturempfindlicher Reagenzien “, says Dolores Schendel, CSO der Medigene AG. “The IFN-Gamma-Biosensor is an innovative tool that has developed an E2E platform, which offers a cost-effective alternative for quantifying the secretion of the secretory IFN-Gamma beet. This biosensor is the best way to determine the time, against the time, The cost and the upgrade of the biosensors can be carried out immediately if the frequency of boiling by T- or NK-Zellen Zeitraumals Standard Endpoint tests.”

The previous poster provided an overview of the established standard method, Enzyme-linked Immunosorbent Assay (ELISA), and the innovative IFN-Gamma-Biosensor, which can make the IFN-Gamma-Freisetzung direct messenger, so that it can also be used in cooking cultures. aerial positions can watch Zellkulturen. The biosensors are so interesting that they produce a green fluorescent protein (GFP) production while expanding IFN-Gamma and quantitative analysis of the GFP fluorescent signals takes place.

The IFN-Gamma Biosensor has comparable empirical performance to the ELISA and can work with standard messages with flow fluctuations and fluorescent radiation that effectively has few IFN-Gamma mirror phases. The detection war is highly qualified for IFN-Gamma, but now there is an exhibit that offers extremely high concentrations of IFN-Gamma or IFN-Gamma, while other interferon types, a minimal response is possible. Weitere in vitro assays have shown that the biosensor dose is very pleasant, while the ELISA test was available, and a longer Kultivierungszeiträume stabilization and empfindlich on IFN-Gamma-Stimulation response. The development of the end-to-end platform is a process optimization technology for high screening tests of T or NK zell functional functions that reduce costs and complexity and achieve a high degree of cost and reproduction. The time of the analysis of the analysis of the analysis that could be carried out was a rapid data transmission and its implementation in robot-controlled Arbeitsabläufe efficiency and rationalization ist.

In combination, the IFN-Gamma Biosensor Technology with its extensive detection capabilities, dynamic messaging over long distances and higher specifications offers an effective and efficient alternative with forward data and a new ELISA with messages from the T and NK Zell functions. Einfache Messungen mit Durchflusszytometry und Fluoreszlesern unterstützen die einfache Integration in Hochdurchsatz-Arbeitsabläufe and senken Kosten en Durchführungszeit.

— End of the press conference —

Uber Medigene AG

Medigene AG (FWB: MDG1) is an immunological platform focused on the Entwicklung of T-Zell-Rezeptor (TCR) treatment with effective treatment by Krebs. The end-to-end platform generates optimal 3S (sensitive, specific and secure) T-Zell receptors with unique and uncontrolled properties, which work in varying therapeutic modes with T-Zell-Rezeptor-modified T-Zell-Therapien (TCR – T), TCR-gesteuerten T-Zell-Engager-Therapien and TCR-Therapien with natural Killerzellen, will develop their own product pipeline as a of the partnerships.

The MDG1015 medical TCR-T program is a potent new TCR-T therapy with expanded solid tumor indications. The end-to-end platform technology works on the T-Zellen, an immunosuppressive tumor microtherapy (TME) with overwinding, and securing the treatment of the T-Zell-Arzneimittelproducts that Maximiert Sicherheit, Wirksamkeit and Beständigkeit der Therapiensprache. Medigene has started implementing the TCR-T program MDG1015 in the 3rd quarter of 2024, the IND-Zulassung and in the 4th quarter of 2024 in the CTA period. For more information, please visit http://www.medigene.de.

Über Medigenes end-to-end platform

Immunotherapy drugs have enormous natural resistance to T-Zell receptors. During the combination of these TCRs with various components of the immune system with T-Zellen, natural Killerzellen (NK) or a CD3-Complex (TCE, T cell Engager), highly specific, effective and specific treatment modalities, which benefit the own peripheral system, were developed. very fun and/or active. Medigene an end-to-end (E2E) platform based on a wealth of robust and modern technology, offering the most advanced TCR-stimulated therapies, a new fortification in TCR-T, TCR-NK and TCR-TCE Arzneimittelproducts. The E2E platform offers the best TCR generation and optimization techniques, with its Allogeneic HLA TCR priming and integrated product enhancement technology with the cost-stimulatory Switch-Protein PD1-41BB and CD40L-CD28 containing the iM-TCR. You can use the E2E platform for the optimal treatment of therapeutic treatment products with comprehensive healthcare, research and best results. Collaboration with partners with BioNTech, Regeneron and WuXi Biologics help develop the platform’s technology and their potential, Krebstherapy is revolutionary.

This Mitteilung is best in the Zukunft-oriented Aussagen. These mirror the Meinung von Medigene zum Datum dieser Mitteilung more broadly. The Medigene tatsächlicherzielten Ergebnisse können von de zkunftsbezogeneen Aussagen erheblich abweichen. Medigene is not obliged to update the relevant information. Medigene® is a brand of Medigene AG. These markers can increase their ownership or ownership of the states.

Aus Gründen der lighter lesbarkeit will have a geschlechterspezifische different representation. Make sure you are in the sin of treatment for both Geschlechter.

Medigene AG Pamela Keck Tel.: +49 89 2000 3333 01 Email: [email protected] (https://medigene.sharepoint.com/sites/MDGCommunications/Freigegebene%20Dokumente/ General/C.%20Press%20releases/PR_released/20240828_Participation%20Herbstkonferenz,%20HCW,%20Baader%20Bank/[email protected] )

If you can no longer find the information about the Medigene information, you can send an email to an email resource ([email protected]). [email protected] were then displayed by an unanswered list of advertisements.

(End)

Aussender: Medigene AG Address: Lochhamer Straße 11, 82152 Planegg/Martinsried Country: Deutschland Contact partner: Medigene PR/IR Tel.: +49 89 2000 3333 01 E-mail: [email protected] Website: www.medigene.de

ISIN(s): DE000A40ESG2 (Action) Börsen: Regulierter Markt in Frankfurt; Freiverkehr in Düsseldorf, Freiverkehr in Hamburg, Freiverkehr in Hannover, Freiverkehr in Munich, Freiverkehr in Stuttgart; Freiverkehr in Berlin, Tradegate

© pressetext Nachrichtenagentur GmbH Pflichtmitteilungen und Finanznachrichten übermittelt durch pressetext. Archive: https://www.pressetext.com/channel/Adhoc . Before you inhale the Mitteilung, the effect is accountable. Contact us for messages: [email protected] or +43-1-81140-300.

(END) Dow Jones Newswires

November 12, 2024 07:00 ET (12:00 GMT)